arrow
T

Taroh Satoh

Graduate School of Medicine
H指数:55
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

High AXL Expression and Stromal–Angiogenic Immune Phenotypes in Upper Gastrointestinal Cancers

高AXL表达和基质-血管生成免疫表型在上消化道癌中的研究

2026-11-110
OAAI
Targeting fibroblast activation protein in solid tumors via LNP-mediated CAR-mRNA delivery promotes durable regression in murine models

通过LNP介导的CAR-mRNA递送靶向实体瘤中的成纤维细胞活化蛋白,在啮齿动物模型中促进持久的肿瘤消退。

2025-12-100
OAAI
Efficacy and safety of irinotecan-based therapy in elderly patients with advanced gastric cancer receiving third-line or later chemotherapy: post-hoc age-subgroup analysis of the rindberg trial

伊立替康为基础的疗法在老年晚期胃癌患者接受三线或更后期化疗中的疗效与安全性:Rindberg试验的事后年龄亚组分析

2025-12-040
PRE
Clinical significance of comprehensive genomic profiling in unresectable or recurrent gastrointestinal stromal tumors: a multicenter retrospective cohort study

不可切除或复发性胃肠道间质瘤综合基因组分析的临床意义:一项多中心回顾性队列研究

2025-11-210
PRE
A multicenter phase II study of eribulin for BRAF V600E mutant metastatic colorectal cancer: the BRAVERY study (EPOC1701)

一项关于厄洛替尼用于BRAF V600E突变型转移性结直肠癌的多中心II期研究:BRAVERY研究(EPOC1701)

2025-10-090
OAAI
Efficacy and safety of fruquintinib in refractory metastatic colorectal cancer: A FRESCO-2 subgroup analysis by age

fruquintinib在难治性转移性结直肠癌中的有效性和安全性:一项基于年龄的FRESCO-2亚组分析

2024-09-010
PRE
Clinical utility of BRCA and ATM mutation status in circulating tumour DNA for treatment selection in advanced pancreatic cancer

循环肿瘤DNA中BRCA和ATM突变状态在晚期胰腺癌治疗选择中的临床应用

2024-08-280
PRE
Clinical features associated with NeoRAS wild-type metastatic colorectal cancer A SCRUM-Japan GOZILA substudy

与NeoRAS野生型转移性结直肠癌相关的临床特征scrum-japan GOZILA子研究

2024-07-131
OAAI
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study
2024-06-010
OAAI
Safety and Efficacy of Encorafenib, Binimetinib, and Cetuximab for BRAFV600E-Mutant Metastatic Colorectal Cancer: Results of the Japanese Expanded Access Program
2024-06-011
OAAI
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
2023-10-0115
PRE
The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)
2023-10-013
OA
Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

TP53基因的突变谱与晚期胃癌的nivolumab治疗效果相关 (TP53MUT研究)

2023-08-024
PRE